Logo image of 0QF.DE

MODERNA INC (0QF.DE) Stock Fundamental Analysis

FRA:0QF - Deutsche Boerse Ag - US60770K1079 - Common Stock - Currency: EUR

22.7  -0.55 (-2.34%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to 0QF. 0QF was compared to 71 industry peers in the Biotechnology industry. 0QF scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. 0QF is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

0QF had negative earnings in the past year.
0QF had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: 0QF reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: 0QF reported negative operating cash flow in multiple years.
0QF.DE Yearly Net Income VS EBIT VS OCF VS FCF0QF.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B

1.2 Ratios

0QF has a Return On Assets (-26.42%) which is comparable to the rest of the industry.
With a decent Return On Equity value of -33.35%, 0QF is doing good in the industry, outperforming 60.56% of the companies in the same industry.
Industry RankSector Rank
ROA -26.42%
ROE -33.35%
ROIC N/A
ROA(3y)-6.14%
ROA(5y)4.17%
ROE(3y)-7.66%
ROE(5y)6.83%
ROIC(3y)N/A
ROIC(5y)N/A
0QF.DE Yearly ROA, ROE, ROIC0QF.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 80

1.3 Margins

With a decent Gross Margin value of 68.68%, 0QF is doing good in the industry, outperforming 66.20% of the companies in the same industry.
In the last couple of years the Gross Margin of 0QF has declined.
0QF does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 68.68%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.55%
GM growth 5YN/A
0QF.DE Yearly Profit, Operating, Gross Margins0QF.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

More info and screens

6

2. Health

2.1 Basic Checks

0QF does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for 0QF has been increased compared to 1 year ago.
Compared to 5 years ago, 0QF has more shares outstanding
Compared to 1 year ago, 0QF has an improved debt to assets ratio.
0QF.DE Yearly Shares Outstanding0QF.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M
0QF.DE Yearly Total Debt VS Total Assets0QF.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B 25B

2.2 Solvency

An Altman-Z score of 3.20 indicates that 0QF is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.20, 0QF belongs to the top of the industry, outperforming 81.69% of the companies in the same industry.
0QF has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.00, 0QF belongs to the top of the industry, outperforming 88.73% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.2
ROIC/WACCN/A
WACC9.99%
0QF.DE Yearly LT Debt VS Equity VS FCF0QF.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B 15B

2.3 Liquidity

0QF has a Current Ratio of 4.22. This indicates that 0QF is financially healthy and has no problem in meeting its short term obligations.
0QF has a better Current ratio (4.22) than 77.46% of its industry peers.
0QF has a Quick Ratio of 4.14. This indicates that 0QF is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of 0QF (4.14) is better than 78.87% of its industry peers.
Industry RankSector Rank
Current Ratio 4.22
Quick Ratio 4.14
0QF.DE Yearly Current Assets VS Current Liabilites0QF.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

More info and screens

6

3. Growth

3.1 Past

0QF shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 44.29%, which is quite impressive.
Looking at the last year, 0QF shows a very negative growth in Revenue. The Revenue has decreased by -38.35% in the last year.
The Revenue has been growing by 122.01% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)44.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%17.92%
Revenue 1Y (TTM)-38.35%
Revenue growth 3Y-44.04%
Revenue growth 5Y122.01%
Sales Q2Q%-35.33%

3.2 Future

0QF is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.49% yearly.
The Revenue is expected to grow by 20.30% on average over the next years. This is a very strong growth
EPS Next Y-12.35%
EPS Next 2Y6.46%
EPS Next 3Y13.02%
EPS Next 5Y18.49%
Revenue Next Year-34.88%
Revenue Next 2Y-15.76%
Revenue Next 3Y-4.3%
Revenue Next 5Y20.3%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
0QF.DE Yearly Revenue VS Estimates0QF.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 5B 10B 15B
0QF.DE Yearly EPS VS Estimates0QF.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 10 -10 20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for 0QF. In the last year negative earnings were reported.
Also next year 0QF is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
0QF.DE Price Earnings VS Forward Price Earnings0QF.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
0QF.DE Per share data0QF.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20

4.3 Compensation for Growth

0QF's earnings are expected to grow with 13.02% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.46%
EPS Next 3Y13.02%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for 0QF!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MODERNA INC

FRA:0QF (5/23/2025, 7:00:00 PM)

22.7

-0.55 (-2.34%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-01 2025-05-01/bmo
Earnings (Next)07-30 2025-07-30/bmo
Inst Owners73.88%
Inst Owner ChangeN/A
Ins Owners5.45%
Ins Owner ChangeN/A
Market Cap8.78B
Analysts64.24
Price Target41.17 (81.37%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)7.48%
Min EPS beat(2)-6.26%
Max EPS beat(2)21.22%
EPS beat(4)3
Avg EPS beat(4)30%
Min EPS beat(4)-6.26%
Max EPS beat(4)101.54%
EPS beat(8)6
Avg EPS beat(8)-10.14%
EPS beat(12)8
Avg EPS beat(12)-0.55%
EPS beat(16)11
Avg EPS beat(16)3.53%
Revenue beat(2)1
Avg Revenue beat(2)0.08%
Min Revenue beat(2)-0.3%
Max Revenue beat(2)0.45%
Revenue beat(4)3
Avg Revenue beat(4)31.23%
Min Revenue beat(4)-0.3%
Max Revenue beat(4)78.74%
Revenue beat(8)7
Avg Revenue beat(8)29.59%
Revenue beat(12)9
Avg Revenue beat(12)24.91%
Revenue beat(16)12
Avg Revenue beat(16)19.49%
PT rev (1m)-14.86%
PT rev (3m)-39.81%
EPS NQ rev (1m)3.44%
EPS NQ rev (3m)-2.31%
EPS NY rev (1m)-0.61%
EPS NY rev (3m)-13.71%
Revenue NQ rev (1m)3.83%
Revenue NQ rev (3m)-31.57%
Revenue NY rev (1m)-3.69%
Revenue NY rev (3m)-14.38%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.12
P/FCF N/A
P/OCF N/A
P/B 0.99
P/tB 1
EV/EBITDA N/A
EPS(TTM)-7.72
EYN/A
EPS(NY)-7.11
Fwd EYN/A
FCF(TTM)-9.23
FCFYN/A
OCF(TTM)-6.98
OCFYN/A
SpS7.27
BVpS23.02
TBVpS22.79
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -26.42%
ROE -33.35%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 68.68%
FCFM N/A
ROA(3y)-6.14%
ROA(5y)4.17%
ROE(3y)-7.66%
ROE(5y)6.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.55%
GM growth 5YN/A
F-Score5
Asset Turnover0.25
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 511.46%
Cap/Sales 30.91%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.22
Quick Ratio 4.14
Altman-Z 3.2
F-Score5
WACC9.99%
ROIC/WACCN/A
Cap/Depr(3y)261.63%
Cap/Depr(5y)224.68%
Cap/Sales(3y)14.96%
Cap/Sales(5y)10.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%17.92%
EPS Next Y-12.35%
EPS Next 2Y6.46%
EPS Next 3Y13.02%
EPS Next 5Y18.49%
Revenue 1Y (TTM)-38.35%
Revenue growth 3Y-44.04%
Revenue growth 5Y122.01%
Sales Q2Q%-35.33%
Revenue Next Year-34.88%
Revenue Next 2Y-15.76%
Revenue Next 3Y-4.3%
Revenue Next 5Y20.3%
EBIT growth 1Y32.09%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-0.67%
EBIT Next 3Y12.82%
EBIT Next 5Y18.31%
FCF growth 1Y-759.15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-407.35%
OCF growth 3YN/A
OCF growth 5YN/A